Nuvalent Presents New Data on Zidesamtinib at AACR 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy NUVL?
Source: PRnewswire
- Clinical Data Presentation: Nuvalent showcased clinical data for zidesamtinib at the 2026 AACR Annual Meeting, focusing on ROS1-positive NSCLC patients previously treated with TKIs, indicating potential efficacy and offering new treatment options for patients.
- FDA Application Progress: Following results from the ARROS-1 clinical trial, the FDA has accepted the NDA submission for zidesamtinib, with a target action date of September 18, 2026, which could expedite market access and enhance Nuvalent's competitive position.
- Breakthrough Therapy Designation: Zidesamtinib has received breakthrough therapy designation for patients previously treated with two or more ROS1 TKIs, highlighting its potential in treating refractory tumors and likely attracting increased investor interest.
- Brain Penetrance Advantage: Designed to improve treatment options for patients with brain metastases, zidesamtinib's unique brain penetrance may avoid adverse effects associated with existing ROS1 inhibitors, thereby enhancing patients' quality of life.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUVL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUVL
Wall Street analysts forecast NUVL stock price to rise
16 Analyst Rating
16 Buy
0 Hold
0 Sell
Strong Buy
Current: 96.720
Low
125.00
Averages
140.86
High
158.00
Current: 96.720
Low
125.00
Averages
140.86
High
158.00
About NUVL
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Latest Wall Street Rating Updates
- UBS Upgrade: UBS upgrades Adecoagro from Neutral to Buy, raising the price target from $8 to $16.2, indicating the company is poised to benefit from the ongoing Middle East conflict, which is expected to enhance its financial performance.
- HSBC Bullish on Carnival: HSBC upgrades Carnival from Hold to Buy, asserting that the current share price undervalues the resilience of experience-led demand, which is likely to improve the company's market performance in the near future.
- Morgan Stanley Reiterates Meta: Morgan Stanley lowers its price target for Meta from $825 to $775 but maintains it as a top investment idea, suggesting that market sentiment has bottomed out, making it an opportune time to buy.
- Deutsche Bank Upgrades Colgate: Deutsche Bank upgrades Colgate-Palmolive from Hold to Buy, highlighting the company's core business as having long-term investment value and the ability to weather current market volatility effectively.
See More
Wells Fargo Begins Coverage of Nuvalent, Inc. with Overweight Rating and $116 Target Price
Company Overview: Nuvalent, Inc. is a company involved in the pharmaceutical sector, focusing on innovative treatments.
Market Activity: The company has initiated coverage with an overweight rating and a target price set at $116.
See More
S&P 500 Futures Decline in Pre-Market Trading; Nuvalent and Figure Tech Solutions Take the Lead
Market Opening: U.S. stock markets are set to open in two hours.
Nuvalent Inc. Performance: Nuvalent Inc. Cl A (NUVL) saw a 7.0% increase in pre-market trading.
Figure Technology Solutions Performance: Figure Technology Solutions Inc. (FIGR) also experienced a 7.0% rise in pre-market trading.
Overall Market Sentiment: The pre-market gains indicate a positive sentiment among investors for these stocks.
See More
Nuvalent (NUVL.US) Executive Plans to Sell $5.73 Million in Common Stock via Form 144
Stock Sale Announcement: Officer Alexandra Balcom intends to sell 59,420 shares of Nuvalent's common stock.
Market Value: The total market value of the shares to be sold is approximately $5.73 million.
See More
Nuvalent Presents New Data on Zidesamtinib at AACR 2026
- Clinical Data Presentation: Nuvalent showcased clinical data for zidesamtinib at the 2026 AACR Annual Meeting, focusing on ROS1-positive NSCLC patients previously treated with TKIs, indicating potential efficacy and offering new treatment options for patients.
- FDA Application Progress: Following results from the ARROS-1 clinical trial, the FDA has accepted the NDA submission for zidesamtinib, with a target action date of September 18, 2026, which could expedite market access and enhance Nuvalent's competitive position.
- Breakthrough Therapy Designation: Zidesamtinib has received breakthrough therapy designation for patients previously treated with two or more ROS1 TKIs, highlighting its potential in treating refractory tumors and likely attracting increased investor interest.
- Brain Penetrance Advantage: Designed to improve treatment options for patients with brain metastases, zidesamtinib's unique brain penetrance may avoid adverse effects associated with existing ROS1 inhibitors, thereby enhancing patients' quality of life.
See More
Nuvalent Presents New Data on Zidesamtinib at AACR 2026
- Clinical Data Presentation: Nuvalent showcased clinical data for zidesamtinib at the 2026 AACR Annual Meeting, focusing on TKI-pretreated patients with ROS1-positive NSCLC, indicating potential efficacy that could offer new treatment options for patients.
- FDA Application Progress: Following results from the ARROS-1 clinical trial, the FDA has accepted the NDA submission for zidesamtinib, with a target action date of September 18, 2026, which, if approved, could provide a new treatment avenue for ROS1-positive NSCLC patients, representing significant market potential.
- Breakthrough Therapy Designation: Zidesamtinib has received breakthrough therapy designation for patients previously treated with two or more ROS1 TKIs, highlighting its unique advantages in treating refractory tumors and potentially improving patient survival rates.
- Brain Penetrance Capability: Designed to overcome limitations of existing ROS1 inhibitors, zidesamtinib exhibits strong brain penetrance, particularly beneficial for patients with brain metastases, potentially reducing TRK-related adverse events and enhancing treatment outcomes.
See More
Latest Wall Street Rating Updates
- UBS Upgrade: UBS upgrades Adecoagro from Neutral to Buy, raising the price target from $8 to $16.2, indicating the company is poised to benefit from the ongoing Middle East conflict, which is expected to enhance its financial performance.
- HSBC Bullish on Carnival: HSBC upgrades Carnival from Hold to Buy, asserting that the current share price undervalues the resilience of experience-led demand, which is likely to improve the company's market performance in the near future.
- Morgan Stanley Reiterates Meta: Morgan Stanley lowers its price target for Meta from $825 to $775 but maintains it as a top investment idea, suggesting that market sentiment has bottomed out, making it an opportune time to buy.
- Deutsche Bank Upgrades Colgate: Deutsche Bank upgrades Colgate-Palmolive from Hold to Buy, highlighting the company's core business as having long-term investment value and the ability to weather current market volatility effectively.
See More
Wells Fargo Begins Coverage of Nuvalent, Inc. with Overweight Rating and $116 Target Price
Company Overview: Nuvalent, Inc. is a company involved in the pharmaceutical sector, focusing on innovative treatments.
Market Activity: The company has initiated coverage with an overweight rating and a target price set at $116.
See More
S&P 500 Futures Decline in Pre-Market Trading; Nuvalent and Figure Tech Solutions Take the Lead
Market Opening: U.S. stock markets are set to open in two hours.
Nuvalent Inc. Performance: Nuvalent Inc. Cl A (NUVL) saw a 7.0% increase in pre-market trading.
Figure Technology Solutions Performance: Figure Technology Solutions Inc. (FIGR) also experienced a 7.0% rise in pre-market trading.
Overall Market Sentiment: The pre-market gains indicate a positive sentiment among investors for these stocks.
See More
Nuvalent (NUVL.US) Executive Plans to Sell $5.73 Million in Common Stock via Form 144
Stock Sale Announcement: Officer Alexandra Balcom intends to sell 59,420 shares of Nuvalent's common stock.
Market Value: The total market value of the shares to be sold is approximately $5.73 million.
See More
Nuvalent Presents New Data on Zidesamtinib at AACR 2026
- Clinical Data Presentation: Nuvalent showcased clinical data for zidesamtinib at the 2026 AACR Annual Meeting, focusing on ROS1-positive NSCLC patients previously treated with TKIs, indicating potential efficacy and offering new treatment options for patients.
- FDA Application Progress: Following results from the ARROS-1 clinical trial, the FDA has accepted the NDA submission for zidesamtinib, with a target action date of September 18, 2026, which could expedite market access and enhance Nuvalent's competitive position.
- Breakthrough Therapy Designation: Zidesamtinib has received breakthrough therapy designation for patients previously treated with two or more ROS1 TKIs, highlighting its potential in treating refractory tumors and likely attracting increased investor interest.
- Brain Penetrance Advantage: Designed to improve treatment options for patients with brain metastases, zidesamtinib's unique brain penetrance may avoid adverse effects associated with existing ROS1 inhibitors, thereby enhancing patients' quality of life.
See More
Nuvalent Presents New Data on Zidesamtinib at AACR 2026
- Clinical Data Presentation: Nuvalent showcased clinical data for zidesamtinib at the 2026 AACR Annual Meeting, focusing on TKI-pretreated patients with ROS1-positive NSCLC, indicating potential efficacy that could offer new treatment options for patients.
- FDA Application Progress: Following results from the ARROS-1 clinical trial, the FDA has accepted the NDA submission for zidesamtinib, with a target action date of September 18, 2026, which, if approved, could provide a new treatment avenue for ROS1-positive NSCLC patients, representing significant market potential.
- Breakthrough Therapy Designation: Zidesamtinib has received breakthrough therapy designation for patients previously treated with two or more ROS1 TKIs, highlighting its unique advantages in treating refractory tumors and potentially improving patient survival rates.
- Brain Penetrance Capability: Designed to overcome limitations of existing ROS1 inhibitors, zidesamtinib exhibits strong brain penetrance, particularly beneficial for patients with brain metastases, potentially reducing TRK-related adverse events and enhancing treatment outcomes.
See More
